Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report

BACKGROUND: Bevacizumab is a monoclonal antibody drug targeting Vascular Endothelial Growth Factor (VEGF), which binds to VEGF receptors to inhibit vascular endothelial cell proliferation and angiogenesis, thus inhibiting tumorigenesis. Pembrolizumab is a monoclonal antibody that can bind to the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanxin, Dong, Changjiang, He, Xucheng, Wu, Pan, Shu, Yamin, Chen, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007831/
https://www.ncbi.nlm.nih.gov/pubmed/36899322
http://dx.doi.org/10.1186/s12882-023-03101-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007831/
https://www.ncbi.nlm.nih.gov/pubmed/36899322
http://dx.doi.org/10.1186/s12882-023-03101-9

Ejemplares similares